Mapping the Metabolic Landscape of Lung Adenocarcinoma: From Energy Flexibility in Early Stages to Glycolytic Entrapment in Advanced Disease

Lung adenocarcinoma, a subtype of non-small cell lung cancer (NSCLC), exhibits profound metabolic reprogramming as it progresses, characterized by a shift from oxidative phosphorylation (OXPHOS) to glycolysis, even in the presence of oxygen. This phenomenon, known as the Warburg effect, enables cancer cells to meet their increased energy and biosynthetic demands, facilitating rapid proliferation and tumor progression. In this study, we compared the metabolic profiles of 150 patients, including 75 with stage 4 lung adenocarcinoma and 75 with early-stage disease (stage I and II), to investigate the dynamic metabolic changes occurring as the disease advances. We analyzed key glycolysis markers—glucose, lactate, and pyruvate—along with oxidative phosphorylation markers—β-hydroxybutyrate, acetoacetate, glutamine, and alanine. The findings revealed a significant increase in glycolysis markers in the stage 4 group, indicating a pronounced shift towards glycolysis. Concurrently, oxidative phosphorylation markers showed a marked reduction, reflecting mitochondrial dysfunction. Additionally, inflammatory cytokines (IL-6, IL-1Beta, TNF-alpha) and lactate dehydrogenase (LDH) were elevated in the advanced-stage patients, contributing to the pro-tumorigenic environment and promoting immune evasion and angiogenesis. Oxidative stress markers, such as melatonin and dopamine, were significantly reduced in stage 4 patients, further underscoring the role of oxidative stress in disease progression. The metabolic reprogramming in lung adenocarcinoma is tightly linked to the tumor microenvironment, supporting immune evasion and metastatic potential. These findings highlight the critical metabolic changes in advanced lung adenocarcinoma and underscore the potential for targeting glycolysis and related pathways as therapeutic strategies. The decline in oxidative phosphorylation and the increase in glycolysis markers suggest a metabolic threshold beyond which traditional anticancer treatments may of